# Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Source: https://onco.cc/trials/nct05709171/  
OnCo record `nct05709171` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Rigshospitalet, Denmark, with a status the registry has not verified recently.

## Summary

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms is a phase 2 interventional study registered as NCT05709171 by Rigshospitalet, Denmark, with 200 participants planned, started 2023-01-17 and due to reach its primary completion in 2025-01-01. Interventions recorded: 18F-FDG, 64Cu-Dotatate. Conditions recorded: GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic.

Linked to the technology Somatostatin receptor PET because the registry names it ("64cu dotatate") among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05709171
- Phase: 2
- Setting: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
- Sponsor: Rigshospitalet, Denmark
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05709171: https://clinicaltrials.gov/study/NCT05709171

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Somatostatin receptor PET (68Ga/64Cu-DOTATATE)](https://onco.cc/technologies/sstr-pet/)

---
JSON: https://onco.cc/api/v1/entities/nct05709171.json